By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468


SEARCH JOBS
NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.


Key Statistics


Email: employment@novabaypharma.com
Ownership: Public

Web Site: NovaBay
Employees:
Symbol: NBY
 









Company News
NovaBay (NBY)'s Avenova Is Breakthrough In Fight Against Contact Lens Intolerance 11/30/2016 12:17:29 PM
NovaBay (NBY) Reports 2016 Third Quarter Financial Results 11/11/2016 12:59:23 PM
NovaBay (NBY) To Hold Third Quarter 2016 Conference Call On November 10 11/3/2016 11:52:11 AM
NovaBay (NBY) Successfully Regains Compliance With NYSE Continued Listing Requirements 10/31/2016 12:34:30 PM
NovaBay (NBY) Receives $7 Million From Early Warrant Exercise 10/3/2016 11:03:17 AM
NovaBay (NBY)’ Auriclosene Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation 9/19/2016 10:27:18 AM
NovaBay (NBY)’ Neutrox Product Line Receives CE Mark And ISO Certification For The European Union 9/12/2016 11:51:42 AM
NovaBay (NBY)'s Neutrox Product Line Nabs CE Mark for the European Union 9/12/2016 7:30:23 AM
NovaBay (NBY) To Present At The Rodman & Renshaw Global Investment Conference 9/6/2016 12:45:07 PM
NovaBay (NBY) Reports 2016 Second Quarter Financial Results 8/12/2016 9:08:55 AM
12345678910...
//-->